H.C. Wainwright upgraded Cidara Therapeutics to Buy from Neutral with a $24 price target. With CD388 reacquired and rezafungin divested, Cidara has a “significantly different outlook” that is now centered around its Cloudbreak drug-Fc conjugate platform, the analyst tells investors in a research note. The firm estimates the risk-adjusted value of CD388 and the market opportunity of Cidara’s DFC oncology program at a total value of $24 per share. It sees “significant upside in Cidara’s DFC programs.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- CDTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cidara Therapeutics files to sell 16.8M shares of common stock for holders
- Cidara Therapeutics Shareholders Decide on Key Corporate Changes
- Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)